NVO ▲ +1.2% - Novo Nordisk A/S $NVO Novo Nordisk: Wegovy Approved in China as First and Only GLP-1 RA for MASH Novo Nordisk shares rose 1.2% following approval of Wegovy in China for metabolic dysfunction-associated fatty liver disease (MASH), marking the first and only GLP-1 receptor agonist cleared in that country for the indication. The approval expands the company's addressable market for the obesity and diabetes drug into one of the world's largest healthcare markets, particularly for a serious liver condition with limited treatment options. 10-SEP-2026 05:16 AM ET